Effect of lobaplatin combined with elemene in the treatment of lung cancer complicated with malignant pleural effusion
Gao Shuhui
Zhang Guibin
Yan Li
Gao Haixiang
Zhang Aili
Xu Jinwei
Su Yan
Pang Bo
Abstract：Objective To investigate the effect of lobaplatin combined with elemene in the treatment of lung cancer complicated with malignant pleural effusion.Methods A total of 60 patients with lung cancer compli-cated with malignant pleural effusion in Hebei General Hospital from July 2019 to July 2022 were selected,and they were randomly divided into control group and observation group according to the random number table method,with 30 cases in each group.The control group was treated with intrathoracic perfusion of lobaplatin,and the observation group was treated with intrathoracic perfusion of lobaplatin and elemene,once a week for 4 weeks.The clinical efficacy,quality of life score,serum tumor marker levels,pleural effusion biochemical indicators and adverse reactions were compared between the two groups.Results After treatment,the remission rate in the observation group was higher than that in the control group[83.3％(25/30)vs 56.7％(17/30)](x2=16.847,P＜0.05).After treatment,the improvement rate of quality of life in the observation group was higher than that in the control group[40.0％(12/30)vs 23.3％(7/30)](X2=6.446,P＜0.05).After treatment,the levels of lactate dehydrogenase,vascular endothelial growth factor and hypoxia inducible factor-1α in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group;the levels of adenosine dehydrogenase in the two groups were higher than those before treatment,and that in the observation group was higher than that in the control group(all P＜0.05).The incidence of adverse reactions in the observation group was lower than that in the control group(P＜0.05).Conclusion Lobaplatin combined with elemene can improve the clinical symptoms and related indicators of patients with lung cancer complicated with malignant pleural effusion,improve the quality of life of patients,and reduce the adverse reactions of lobaplatin.
Keywords：Lung cancerMalignant pleural effusionLobaplatinElemeneIntrathoracic perfusion
Publication Date：2023-12-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 1802-1806 )